3Brain sits in the ex vivo electrophysiology tools segment, differentiated by its bidirectional CMOS-MEA arrays at 4,096-electrode density, a specification tier above most competing platforms in the organoid and brain-slice research market. With no disclosed clinical or in vivo pathway, its microchip-based technology is best understood as research infrastructure rather than translational technology.